Clinical Trials Browser

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT07222631 2026-03-05

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

Phase 1/2 Recruiting

48 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT07294677 2026-03-04

CAVALRY

Phase 1/2 Recruiting

104 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT06364423 2026-03-02

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Phase 1/2 Recruiting

132 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Phase 1/2 Active not recruiting

438 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT05551936 2026-02-17

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Phase 1/2 Active not recruiting

42 enrolled

Lymphoid

Lymphoma, Follicular

NCT02158091 2026-02-13

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Phase 1/2 Active not recruiting

32 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06644183 2026-02-11

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Recruiting

64 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04669171 2026-01-30

SIDNEY

Phase 1/2 Recruiting

80 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 4 FDA

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

EPCORE™ CLL-1

Soundtrack-E

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

EPCORE™ NHL-3

EPCORE™ NHL-2

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

iMATRIX GLO

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

CAVALRY

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

SIDNEY

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL